Considerations for using potential surrogate endpoints in cancer screening trials

The requirement of large-scale expensive cancer screening trials spanning decades creates considerable barriers to the development, commercialisation, and implementation of novel screening tests. One way to address these problems is to use surrogate endpoints for the ultimate endpoint of interest, c...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Lancet Oncol
Asıl Yazarlar: Webb, Alexis B, Berg, Christine D, Castle, Philip E, Crosby, David, Etzioni, Ruth, Kessler, Larry G, Menon, Usha, Parmar, Mahesh, Steele, Robert J C, Sasieni, Peter D
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2024
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7616115/
https://ncbi.nlm.nih.gov/pubmed/38697164
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(24)00015-9
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller